Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

difficulty breathing at rest
granulocyte colony stimulating factor
positron emission tomography
pulse oximetry
18f-fdg
  • 0 views
  • 19 Feb, 2024
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

refractory hepatoblastoma
hodgkin's disease
cancer
donor lymphocyte infusion
recurrent who grade ii glioma
  • 0 views
  • 19 Feb, 2024
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

This prospectivemulti-centeropen-label, controlled study will evaluate the efficacy and safety of targeted drug in combination with CHOP in treatment of newly diagnosed peripheral T-cell lymphoma.

t-cell lymphoma
peripheral t-cell lymphoma
pet/ct scan
lymphoma
measurable disease
  • 0 views
  • 19 Feb, 2024
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.

t-cell lymphoma
tucidinostat
pet/ct scan
lymphoma
measurable disease
  • 0 views
  • 19 Feb, 2024
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

marginal zone lymphoma
cyclophosphamide
epirubicin
prednisone
rituximab
  • 0 views
  • 19 Feb, 2024
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.

serum bilirubin
cancer therapy
positron emission tomography
cancer
ct scan
  • 0 views
  • 19 Feb, 2024
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.

cancer
hematologic malignancy
flow cytometry
ejection fraction
leukemia
  • 0 views
  • 19 Feb, 2024
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy

cancer
lymphoblastic lymphoma
hematologic malignancy
flow cytometry
follicular lymphoma
  • 0 views
  • 19 Feb, 2024
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

serum pregnancy test
bone marrow biopsy
platelet transfusion
cancer
myd88 gene mutation
  • 0 views
  • 19 Feb, 2024
Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas

Describe the treatment of B-cell non-Hodgkin lymphoma patients who receive lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs), and evaluate the efficacy and safety of lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs) in the real-world setting.

non-hodgkin lymphoma
hodgkin's disease
lenalidomide
rituximab
lymphoma
  • 0 views
  • 19 Feb, 2024